"The Invisiport has many benefits for patients who require long-term venous access," said Dr. Anthony Nelson, General and Vascular Surgeon at Wheaton Franciscan Medical Group.
Madison, Wis. (PRWEB) July 29, 2015
Stealth Therapeutics Inc. announced today that it has enrolled its first two patients in a Clinical Performance Study for the Invisiport at Wheaton Franciscan Healthcare in Milwaukee, Wis. The Invisiport product line, which now includes 4.4 and 6 French catheter options, offers a less invasive, patient-friendly alternative to traditional chest ports and peripherally inserted central catheters (PICCs). It is intended for use in patients requiring long-term intravenous treatment for cancer or infectious disease.
The U.S. Food and Drug Administration has cleared both the 4.4 and 6 French Invisiport variations. The goal for the Clinical Performance Study is to collect data, which demonstrates the advantages that the Invisiport provides to patients. Dr. Anthony Nelson, General and Vascular Surgeon at Wheaton Franciscan Medical Group, is a Principal Investigator for the Study.
“The Invisiport has many benefits for patients who require long-term venous access. Because it is easier to place than traditional chest ports and does not require sedation, it’s easier on the patient and appears to pose a lower risk of major complications such as pneumothorax and arterial puncture,” said Dr. Nelson. “Patients also appreciate the cosmetic benefits with a smaller, well hidden incision and lower profile port that doesn’t protrude like traditional ports,” he added.
Stealth’s Invisiport product provides the same function as conventional implanted ports, but features a patented self-deploying wing that minimizes insertion size and provides increased stability once implanted in a patient’s arm. Patients benefit from a smaller incision, and a smaller incision may mean faster implant procedures.
“We are pleased to announce the enrollment of our first patients in the Clinical Performance Study,” said Sam Adams, general manager at Stealth Therapeutics. “We believe that the data we collect will demonstrate the patient-focused benefits of the Invisiport compared to alternatives. Our ultimate goal is to improve quality of life for patients, who require treatment through vascular access devices throughout the country.”
About Stealth Therapeutics Inc.
Stealth Therapeutics is a revenue-stage company that was founded for the purpose of designing and developing a portfolio of patented venous-access devices. The FDA cleared the first Invisiport product in 2011. There are more than 10 patients currently receiving treatment through an Invisiport. Kegonsa Capital Partners (KCP) was the seed investor in Stealth Therapeutics and is the company’s single largest shareholder. KCP is a venture capital fund based in Madison, Wis. For more information about Stealth Therapeutics Inc., please visit http://www.stealththerapeutics.com.
About Wheaton Franciscan Healthcare
Wheaton Franciscan Healthcare is a Catholic, not-for-profit organization with more than 100 sites in Wisconsin, Iowa, and Illinois including 14 hospital campuses, three transitional and extended care facilities, two home health agencies, nearly 3,000 physicians, 70 clinic sites with more than 500 employed physicians, and more than 17,000 associates. Started more than 130 years ago and formally incorporated in 1983, the System is sponsored by the Wheaton Franciscan Sisters. Corporate services offices are located in Wheaton, Illinois and Glendale, Wisconsin.
The System also operates a housing division known as Franciscan Ministries with 2,620 units of assisted living and other housing.